Analysis of the Bronchopulmonary Dysplasia Treatment Market by Bronchodilators, Diuretics, Antibiotics, Steroids, Immunomodulators, and Surfactant Homeostasis
From Wheezers to Wonder! Bronchopulmonary Dysplasia Treatment Ignites Infant Healing- Get More Insights with FMI
Bronchopulmonary Dysplasia Treatment Market Outlook
The global bronchopulmonary dysplasia treatment market is expected to garner a market value of US$ 385.6 million in 2023 and is expected to accumulate US$ 700.2 million by registering a CAGR of 6.1% in the forecast period.
The market growth is attributed to the increasing cases of bronchopulmonary dysplasia along with the rise in premature births across the globe.
The market registered a CAGR of 5.0% in the historical period 2018 to 2022. Bronchopulmonary dysplasia is a chronic respiratory disease, which most commonly occurs in premature infants who received supplemental oxygen or mechanical ventilation. It is also called respiratory distress syndrome. In addition, bronchopulmonary dysplasia also occurs in infants who experience abnormal lung development or had a pre-birth antenatal infection.
Most infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition causes serious complications during infancy and requires hospitalization and intensive medical care, during the first 2 years after birth.
The signs and symptoms of BPS include shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation.
The disease is caused by other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, which affects the development of the lungs.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
What are the Challenges Faced by the Bronchopulmonary Dysplasia Treatment Industry?
Long-term side effects of drugs in certain cases are becoming a matter of concern for certain infants. This, in turn, is creating obstacles to market growth. Moreover, the high cost of treatment owing to the complex nature of the disease is another factor impeding the market growth.
Lack of awareness in developing countries leaves many infants undiagnosed. This, in turn, is increasing the death rate of infants. All these factors are derailing the progress of the bronchopulmonary dysplasia treatment sector.
Attributes
Details
Bronchopulmonary Dysplasia Treatment Market CAGR (2023 to 2033)
2018 to 2022 Bronchopulmonary Dysplasia Treatment Demand Analysis vs. Forecast 2023 to 2033
The global demand for bronchopulmonary dysplasia treatment is projected to increase at a CAGR of 6.1% during the forecast period, reaching a total of US$ 700.2 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.0%.
The prevalence of the COVID-19 pandemic brought in the fear of bronchopulmonary dysplasia among healthcare professionals and parents. Thus, the demand for the treatment of the same increased drastically. Moreover, most healthcare facilities are preparing special units for the treatment of bronchopulmonary dysplasia.
Most end-user industries such as nursing homes and hospitals are ready with equipment that help in diagnosing and treating bronchopulmonary dysplasia. This, in turn, is favoring the growth of the market in the assessment period.
Find your sweet spots for generating winning opportunities in this market.
Which are Some Prominent Drivers of the Bronchopulmonary Dysplasia Treatment Industry?
According to the Airway estimates, in Europe and the United States, up to 160,000 infants are at high risk for the development of BPD collectively, each year. Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and a raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of the bronchopulmonary dysplasia treatment market over the forecast period.
Growing research and development activities by pharmaceutical companies to develop innovative treatment options for bronchopulmonary dysplasia boost the market in near future.
Companies are focusing on the development of novel treatment options for bronchopulmonary dysplasia for faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia.
On the other hand, research is developing stem cell therapy for novel therapeutic modalities for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in preterm infants.
Comparative View of the Market
Bronchopulmonary Dysplasia Treatment Market:
Attributes
Bronchopulmonary Dysplasia Treatment Market
CAGR (2023 to 2033)
6.1%
Market Value (2033)
US$ 700.2 million
Growth Factor
Rising number of treatments
Opportunity
Increasing healthcare facilities
Trends
Extensive research and treatment options
Bronchoscopes Market:
Attributes
Bronchoscopes Market
CAGR (2023 to 2033)
4.4%
Market Value (2033)
US$ 803.30 million
Growth Factor
Increasing elderly population
Opportunity
Rising diseases due to changing lifestyles
Trends
Shift from conventional invasive surgeries
Bronchitis Treatment Market:
Attributes
Bronchitis Treatment Market
CAGR (2023 to 2033)
4.1%
Market Value (2033)
US$ 5,730 million
Growth Factor
Rising geriatric population
Opportunity
Rising government-led initiatives
Trends
Surging healthcare expenditure
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Regional Analysis
Countries
Market Share (2022)
United States
35.6%
Germany
7.8%
Japan
3.0%
Technological Advancements Creating Lucrative Opportunities for the Bronchopulmonary Dysplasia Treatment Sector in North America?
North America is expected to dominate the global market for bronchopulmonary dysplasia treatment due to favorable government policies, increased awareness about bronchopulmonary dysplasia, and high treatment rates are expected to drive the growth of the market over the forecast period.
Advancements in the healthcare sector along with continuous research and development in treating bronchopulmonary dysplasia is favoring market growth, especially in the United States. Thus, due to the reasons mentioned above, North America held 41.2% market share in 2022.
Increasing Deaths of Infants Bolstering Early Diagnosis of Bronchopulmonary Dysplasia Treatment Industry in Europe?
Country
United Kingdom
Market CAGR (2023 to 2033)
5.2%
Europe is witnessing a growth in the number of infants suffering from bronchopulmonary dysplasia. This is owing to the disease becoming more common in the region. In addition, most cases of bronchopulmonary dysplasia are undiagnosed, increasing the deaths of infants at an alarming rate. This has led to healthcare facilities in the region specifically paying attention to the cause of the diseases.
The strong presence of healthcare sectors in the Netherlands along with government policies working in the favor of childcare are accelerating the growth of the market. Thus, owing to the aforementioned reasons, Europe possessed 37.2% market share in 2022.
Increasing Awareness and Favorable Policies Accelerating Market Growth in Asia Pacific?
Countries
Market CAGR (2023 to 2033)
China
9.1%
India
7.4%
With 73.6 million live births in Asia Pacific and a preterm rate of <32 weeks of approximately 2.2%, the demand for bronchopulmonary dysplasia treatment has grown over time. A rise in awareness toward the treatment of the disease and an increase in healthcare expenditure is expected to boost the market growth.
A large patient pool along with government programs and initiatives are the key factors influencing the market growth in Asia Pacific. Thus, Asia Pacific procured a 35% market share in 2022.
Category-Wise Insights
Effectiveness of Supplemental Oxygen Therapy a Dependable Treatment Option for Bronchopulmonary Dysplasia Treatment?
The oxygen therapy segment is expected to hold a significant share of the global market during the forecast period due to factors such as the effectiveness of drugs and more commonly used therapy.
In addition, oxygen supplement is an effective therapy with no risks involved and is safe for infants, making it a favorable option for treatment. Thus, supplemental oxygen supplement therapy held a 35.8% market share in 2022.
Availability of Different Treatments Making Hospitals a Feasible Option for Bronchopulmonary Dysplasia Treatment Industry?
Based on end-users, the global market is classified into hospitals, nursing homes, critical care units, and others. Amongst these, hospitals are expected to hold a significant share owing to the facilities and equipment they possess.
Most hospitals offer a variety of treatments for bronchopulmonary dysplasia making it feasible for immediate diagnosis and treatments. Thus, hospitals possessed a 47.5% market share in 2022.
Start-ups in the Bronchopulmonary Dysplasia Treatment Industry
Key bronchopulmonary dysplasia treatment start-ups are AyuVis, Exvastat, Altavant Sciences, Atriva Therapeutics, ReAlta Life Sciences, and Omnispirant.
In May 2022, AyuVis secured $1.8 Million through Small Business Innovation Research Grant to support the research of its investigational product (AVR-48) targeting the market.
Altavant, a key start-up in the bronchopulmonary dysplasia treatment sector, is focusing on creating small-molecule inhibitors for respiratory disorders.
Market Competition
Attention was drawn to modifying treatment regimens in accordance with the unique patient features and severity of the condition. Approaches to personalized medicine aimed to improve results and lessen treatment adverse effects. The pathophysiology of bronchopulmonary dysplasia was extensively researched, and possible treatment targets were found in large part by universities and research organizations. These findings helped to design novel therapeutic strategies and enhance patient outcomes.
In March 2022, Airway Therapeutics LLC announced the dosing of the first patient in the Phase 1b randomized trial AT-100 (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD). The clinical trial of the drug is expected to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.
Chiesi Farmaceutici SpA, a key player in the bronchopulmonary dysplasia treatment industry, is focusing on research for newer treatments and effective drugs that increase recovery rate and reduce pain.
Key Players
Airway Therapeutics LLC
Chiesi Farmaceutici SpA
Insmed Incorporated
MediPost Co. Ltd.
Meridian Biotech Co. Ltd
Syntrix Biosystems Inc.
Martindale Pharmaceuticals
Takeda
Mallinckrodt
AdventHealth
Key Segments
By Drug Type:
Bronchodilators
Diuretics
Antibiotics
Steroids
Immunomodulators
Surfactant Homeostasis
By Therapy Type:
Nitric Oxide Therapy
Protein replacement therapy
Stem Cell Therapy
Supplemental Oxygen
By End User:
Hospitals
Nursing Homes
Critical Care Centers
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Frequently Asked Questions
What is the Growth Potential of the Market?
The market is forecast to register a CAGR of 6.1% through 2033.
What is the Projected Size of the Market by 2033?
The market is valued to reach US$ 700.2 million by 2033.
What Historical Changes Did the Market Undergo?
The global market advanced at a 5% HCAGR from 2018 to 2022.
How Big is the Bronchopulmonary Dysplasia Treatment Market?
The market to secure a valuation of US$ 385.6 million in 2023.
Which Section Can Acquire Significance by Therapy Type?
The supplemental oxygen supplement therapy sector comprises 35.8% of the market share.
Which End-user Segment to Capture a Significant Market Share?
The hospital category garners 47.5% of the market.
What Size is the Chinese Market?
China market is set to expand at a 9.1% CAGR.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. Bronchodilators
5.3.2. Diuretics
5.3.3. Antibiotics
5.3.4. Steroids
5.3.5. Immunomodulators
5.3.6. Surfactant Homeostasis
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033
6.3.1. Nitric Oxide Therapy
6.3.2. Protein Replacement Therapy
6.3.3. Stem Cell Therapy
6.3.4. Supplemental Oxygen
6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Nursing Homes
7.3.3. Critical Care Centers
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Type
9.2.3. By Therapy Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Therapy Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Type
10.2.3. By Therapy Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Therapy Type
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Drug Type
11.2.3. By Therapy Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Therapy Type
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Drug Type
12.2.3. By Therapy Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Therapy Type
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Drug Type
13.2.3. By Therapy Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Therapy Type
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Type
14.2.3. By Therapy Type
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Therapy Type
14.3.4. By End User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Type
15.2.3. By Therapy Type
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Type
15.3.3. By Therapy Type
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Type
16.1.2.2. By Therapy Type
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Type
16.2.2.2. By Therapy Type
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Type
16.3.2.2. By Therapy Type
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Type
16.4.2.2. By Therapy Type
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Type
16.5.2.2. By Therapy Type
16.5.2.3. By End User
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Type
16.6.2.2. By Therapy Type
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Type
16.7.2.2. By Therapy Type
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Type
16.8.2.2. By Therapy Type
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Type
16.9.2.2. By Therapy Type
16.9.2.3. By End User
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Type
16.10.2.2. By Therapy Type
16.10.2.3. By End User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Type
16.11.2.2. By Therapy Type
16.11.2.3. By End User
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Type
16.12.2.2. By Therapy Type
16.12.2.3. By End User
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Type
16.13.2.2. By Therapy Type
16.13.2.3. By End User
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Type
16.14.2.2. By Therapy Type
16.14.2.3. By End User
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Type
16.15.2.2. By Therapy Type
16.15.2.3. By End User
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Type
16.16.2.2. By Therapy Type
16.16.2.3. By End User
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Type
16.17.2.2. By Therapy Type
16.17.2.3. By End User
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Type
16.18.2.2. By Therapy Type
16.18.2.3. By End User
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Type
16.19.2.2. By Therapy Type
16.19.2.3. By End User
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Type
16.20.2.2. By Therapy Type
16.20.2.3. By End User
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Type
16.21.2.2. By Therapy Type
16.21.2.3. By End User
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Drug Type
16.22.2.2. By Therapy Type
16.22.2.3. By End User
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Drug Type
16.23.2.2. By Therapy Type
16.23.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Type
17.3.3. By Therapy Type
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Airway Therapeutics LLC
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Chiesi Farmaceutici SpA
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Insmed Incorporated
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. MediPost Co. Ltd.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Meridian Biotech Co. Ltd
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Syntrix Biosystems Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Martindale Pharmaceuticals
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Takeda
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Mallinckrodt
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. AdventHealth
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 15: Western Europe Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033
Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: East Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 27: East Asia Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033
Table 28: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Therapy Type, 2018 to 2033
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Therapy Type, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Therapy Type, 2023 to 2033
Figure 19: Global Market Attractiveness by End User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Therapy Type, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Therapy Type, 2023 to 2033
Figure 39: North America Market Attractiveness by End User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Therapy Type, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Therapy Type, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 62: Western Europe Market Value (US$ Million) by Therapy Type, 2023 to 2033
Figure 63: Western Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 71: Western Europe Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 77: Western Europe Market Attractiveness by Drug Type, 2023 to 2033
Figure 78: Western Europe Market Attractiveness by Therapy Type, 2023 to 2033
Figure 79: Western Europe Market Attractiveness by End User, 2023 to 2033
Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 82: Eastern Europe Market Value (US$ Million) by Therapy Type, 2023 to 2033
Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 97: Eastern Europe Market Attractiveness by Drug Type, 2023 to 2033
Figure 98: Eastern Europe Market Attractiveness by Therapy Type, 2023 to 2033
Figure 99: Eastern Europe Market Attractiveness by End User, 2023 to 2033
Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia and Pacific Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 102: South Asia and Pacific Market Value (US$ Million) by Therapy Type, 2023 to 2033
Figure 103: South Asia and Pacific Market Value (US$ Million) by End User, 2023 to 2033
Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033
Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 117: South Asia and Pacific Market Attractiveness by Drug Type, 2023 to 2033
Figure 118: South Asia and Pacific Market Attractiveness by Therapy Type, 2023 to 2033
Figure 119: South Asia and Pacific Market Attractiveness by End User, 2023 to 2033
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 121: East Asia Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 122: East Asia Market Value (US$ Million) by Therapy Type, 2023 to 2033
Figure 123: East Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 124: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: East Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 131: East Asia Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033
Figure 134: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 137: East Asia Market Attractiveness by Drug Type, 2023 to 2033
Figure 138: East Asia Market Attractiveness by Therapy Type, 2023 to 2033
Figure 139: East Asia Market Attractiveness by End User, 2023 to 2033
Figure 140: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 141: Middle East and Africa Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 142: Middle East and Africa Market Value (US$ Million) by Therapy Type, 2023 to 2033
Figure 143: Middle East and Africa Market Value (US$ Million) by End User, 2023 to 2033
Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Therapy Type, 2018 to 2033
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Therapy Type, 2023 to 2033
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Therapy Type, 2023 to 2033
Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 157: Middle East and Africa Market Attractiveness by Drug Type, 2023 to 2033
Figure 158: Middle East and Africa Market Attractiveness by Therapy Type, 2023 to 2033
Figure 159: Middle East and Africa Market Attractiveness by End User, 2023 to 2033
Figure 160: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
